Clinical Trials Browser

Phase 2 × elotuzumab × 30 days × Clear all

NCT03361306 2026-03-06

LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma

Phase 2 Completed

15 enrolled 26 charts

Multiple Myeloma, Recurrence